Part 1 - Watch the video lecture 1 and answer the following questions:

1. Which was the innovation pathway followed by low- and middle-income countries (LMICs) to develop their pharmaceutical innovation system most highlighted in the video?
   A: Patent protection
   B: Imitation to innovation
   C: “Blockbuster” innovation model
   D: Open innovation model

2. Which source of funding to conduct pharmaceutical research and development activities in LMICs was NOT mentioned in the video?
   A: Sales of generic medicines
   B: Government funding
   C: Venture capital
   D: Philanthropic funding

3. Which policy was NOT mentioned in the video for building pharmaceutical R&D capacities in LMICs?
   A: Mandatory local manufacturing policies
   B: Mandatory clinical trials in the country
   C: Policies linking industrial and/or technological development with public health needs
   D: Multinational pharmaceutical companies access strategies in LMICs

4. Which one of these is NOT a challenge faced by LMICs to conduct pharmaceutical R&D identified in the video?
   A: Lack of enabling policy frameworks
   B: Limited financial and human resources
   C: Lack of patent protection for pharmaceuticals
   D: Limited public or private investment

Part 2 - Watch the video lecture 2 and answer the following questions:

5. Which type of disease was most researched in clinical trials conducted in LMICs?
   A: infectious and parasitic diseases
   B: respiratory diseases
   C: maternal health
   D: malignant neoplasms

6. TRUE or FALSE. Indicators showed growing capacity in the riskier, more innovative, earlier stages of R&D in LMICs.
   A: TRUE
   B: FALSE

7. TRUE or FALSE. Most of the clinical trials in LMICs were sponsored and funded by non-commercial actors.
   A: TRUE
   B: FALSE